https://www.selleckchem.com/PI3K.html
d without comorbidities. In the Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction (EMPEROR-Preserved), empagliflozin significantly reduced hospitalizations for heart failure while improving patient-reported health status compared with placebo. The long-term cost-effectiveness of empagliflozin among patients who have heart failure with preserved ejection fraction (HFpEF) remains unclear. To estimate the cost-effectiveness of empagliflozin in patients with HFpEF. This cost-effectiveness analysis perfo
Aimer
Commentaire
Partagez
